» Articles » PMID: 16421421

Astragalus-based Chinese Herbs and Platinum-based Chemotherapy for Advanced Non-small-cell Lung Cancer: Meta-analysis of Randomized Trials

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2006 Jan 20
PMID 16421421
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Systemic treatments for advanced non-small-cell lung cancer have low efficacy and high toxicity. Some Chinese herbal medicines have been reported to increase chemotherapy efficacy and reduce toxicity. In particular, Astragalus has been shown to have immunologic benefits by stimulating macrophage and natural killer cell activity and inhibiting T-helper cell type 2 cytokines. Many published studies have assessed the use of Astragalus and other Chinese herbal medicines in combination with chemotherapy. We sought to evaluate evidence from randomized trials that Astragalus-based Chinese herbal medicine combined with platinum-based chemotherapy (versus platinum-based chemotherapy alone) improves survival, increases tumor response, improves performance status, or reduces chemotherapy toxicity.

Methods: We searched CBM, MEDLINE, TCMLARS, EMBASE, Cochrane Library, and CCRCT databases for studies in any language. We grouped studies using the same herbal combinations for random-effects meta-analysis.

Results: Of 1,305 potentially relevant publications, 34 randomized studies representing 2,815 patients met inclusion criteria. Twelve studies (n = 940 patients) reported reduced risk of death at 12 months (risk ratio [RR] = 0.67; 95% CI, 0.52 to 0.87). Thirty studies (n = 2,472) reported improved tumor response data (RR = 1.34; 95% CI, 1.24 to 1.46). In subgroup analyses, Jin Fu Kang in two studies (n = 221 patients) reduced risk of death at 24 months (RR = 0.58; 95% CI, 0.49 to 0.68) and in three studies (n = 411) increased tumor response (RR = 1.76; 95% CI, 1.23 to 2.53). Ai Di injection (four studies; n = 257) stabilized or improved Karnofsky performance status (RR = 1.28; 95% CI, 1.12 to 1.46).

Conclusion: Astragalus-based Chinese herbal medicine may increase effectiveness of platinum-based chemotherapy when combined with chemotherapy. These results require confirmation with rigorously controlled trials.

Citing Articles

Comparison of the Immune Enhancing Activity and Chemical Constituents Between Imitation Wild and Cultivated Astragali Radix.

Zhao S, Li X, Wang Y, Xu R, Li X, Liu J Molecules. 2025; 30(4).

PMID: 40005233 PMC: 11858062. DOI: 10.3390/molecules30040923.


Recent efficacy and long-term survival of polysaccharide combined with gemcitabine and S-1 in pancreatic cancer.

Li G, Jiang J World J Clin Oncol. 2024; 15(11):1404-1411.

PMID: 39582615 PMC: 11514418. DOI: 10.5306/wjco.v15.i11.1404.


Chinese herbal medicine for the treatment of intestinal cancer: preclinical studies and potential clinical applications.

Zhang J, Wu Y, Tian Y, Xu H, Lin Z, Xian Y Mol Cancer. 2024; 23(1):217.

PMID: 39354520 PMC: 11443726. DOI: 10.1186/s12943-024-02135-3.


Astragalus Polysaccharides and Metformin May Have Synergistic Effects on the Apoptosis and Ferroptosis of Lung Adenocarcinoma A549 Cells.

Lee I, Wang T, Kuo Y, Shih W, Yang P, Hsu C Curr Issues Mol Biol. 2024; 46(8):7782-7794.

PMID: 39194678 PMC: 11352293. DOI: 10.3390/cimb46080461.


Shenqi Fuzheng Injection Reduces Cisplatin-Induced Kidney Injury via cGAS/STING Signaling Pathway in Breast Cancer Mice Model.

Ma Y, Bai B, Liu D, Shi R, Zhou Q Breast Cancer (Dove Med Press). 2024; 16:451-469.

PMID: 39165276 PMC: 11335009. DOI: 10.2147/BCTT.S475860.